8-K: BeautyHealth Reports Mixed Q1 2024 Results, Net Sales Decline Offset by Cost Management

The Beauty Health Company reported a 5.7% decrease in net sales for the first quarter of 2024, but improved profitability through cost management and debt repurchases.

Summary

• The Beauty Health Company announced its financial results for the first quarter of 2024, with net sales reaching $81.4 million, a 5.7% decrease compared to the same period last year.
• This decline was primarily due to lower sales of delivery systems, which was partially offset by growth in consumables net sales.
• The company's gross profit was $48.4 million, with a gross margin of 59.4%, down from 62.7% in the prior year.
• Adjusted gross profit was $51.6 million, with an adjusted gross margin of 63.4%, compared to 70.0% in the first quarter of 2023.
• The net loss for the quarter was $(0.7) million, a significant improvement from the $(20.3) million loss in the same quarter of the previous year, primarily due to a gain on the repurchase of convertible notes.
• Adjusted EBITDA was $0.4 million, compared to $(0.5) million in the first quarter of 2023, driven by lower operating expenses.
• The company repurchased $192.3 million of convertible notes through May 8th, 2024, reducing its debt.
• The company sold 1,417 delivery systems in the quarter, compared to 1,774 in the prior year period.
• The active install base of delivery systems reached 32,530, up from 27,406 in the prior year.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company has made progress in reducing losses and improving EBITDA, the decrease in net sales and gross margin is concerning. The debt repurchase is a positive sign, but the overall financial performance is mixed.

Positives

• The company's net loss improved significantly, moving from a loss of $(20.3) million to a loss of $(0.7) million year-over-year.
• Adjusted EBITDA turned positive, increasing from $(0.5) million to $0.4 million year-over-year.
• The company successfully repurchased $192.3 million of convertible notes, reducing its debt.
• Consumables net sales increased year-over-year, indicating continued demand for the company's products.
• The active install base of delivery systems grew to 32,530, up from 27,406 in the prior year.

Negatives

• Net sales decreased by 5.7% year-over-year, primarily due to lower delivery system sales.
• Gross margin decreased from 62.7% to 59.4% year-over-year.
• Adjusted gross margin decreased from 70.0% to 63.4% year-over-year.
• The company sold fewer delivery systems in Q1 2024 compared to Q1 2023, with 1,417 units sold versus 1,774.

Risks

• The company faces a challenging year-over-year comparison in the second quarter due to the international launch of Syndeo in the comparable 2023 period.
• The company's financial guidance assumes no material deterioration in general market conditions or other unforeseen circumstances.
• The company's financial guidance excludes any unannounced acquisitions, dispositions, or financings.
• The company's gross margin and adjusted gross margin were adversely impacted by higher indirect product costs and inventory related charges.

Future Outlook

The company expects net sales to be between $96 million and $102 million for the second quarter of 2024, with adjusted EBITDA between $4 million and $7 million. For the full fiscal year 2024, the company anticipates flat to low-single digit percentage growth in net sales and adjusted EBITDA greater than $40 million, with growth weighted towards the second half of the year, particularly the fourth quarter.

Management Comments

• Our first quarter results demonstrate the progress we are making on our near-term strategic priorities, including sales excellence, operational excellence, and financial discipline, said BeautyHealth Chief Executive Officer Marla Beck.
• I am confident that our continued execution of our business transformation strategy will lay the foundation for future growth.
• By focusing on our providers and the clinically proven efficacy of the Hydrafacial treatment system, we will ensure our flagship brand remains a leading facial treatment in aesthetics while we continue to unlock its potential with providers and consumers across the globe.

Industry Context

The beauty and aesthetics industry is competitive, with companies focusing on innovative treatments and technologies. BeautyHealth's focus on its Hydrafacial brand and its strategic priorities aligns with the industry's emphasis on clinically proven efficacy and provider relationships. The company's performance is being impacted by the timing of product launches and the need to strengthen customer confidence in new products.

Comparison to Industry Standards

• Comparing BeautyHealth to companies like InMode and Cutera, which also operate in the aesthetic device market, shows that BeautyHealth's revenue decline is a concern, as these companies have shown more robust growth in recent quarters.
• While BeautyHealth's adjusted EBITDA is improving, it is still relatively low compared to industry leaders, indicating a need for further operational efficiencies.
• The repurchase of convertible notes is a positive step, but the company's cash position has decreased, which could limit future investment opportunities compared to peers with stronger cash reserves.
• The decrease in delivery system sales is a concern, as it suggests a potential slowdown in the adoption of their technology compared to competitors who are seeing growth in device sales.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net sales but encouraged by the improved profitability and debt reduction.
• Employees may be impacted by the company's focus on operational excellence and cost management.
• Customers may benefit from the company's focus on the efficacy of the Hydrafacial treatment system.
• Suppliers may be affected by changes in the company's purchasing patterns.

Next Steps

• The company will host a conference call on May 9, 2024, to discuss the first quarter 2024 financial results.
• The company will continue to execute its business transformation strategy.
• The company will focus on strengthening customer confidence in Syndeo.

Key Dates

Keywords

Hydrafacial, BeautyHealth, Financial Results, Net Sales, EBITDA, Gross Margin, Convertible Notes, Debt Repurchase, Consumables, Delivery Systems